Ergot derivatives have been used in the treatment of migraine for more than 50 years. We have compared the efficacy of dihydroergotamine (DHE) nasal spray with that of placebo in patients with classic or common migraine attacks. The study was performed in accordance with a double-blind, crossover design. In this study a great placebo effect was observed with a dose of 1.36 mg/attack, and the overall efficacy was rated by the patients to be 41% and 52% for placebo and DHE, respectively.
BerdeBSchildHOWeilC edsPharmacology and clinical pharmacology of dihydroergotamine.Berlin: Springer-Verlag1981.
2.
BousserMGLoriaY.Efficacy of dihydroergotamine nasal spray in the acute treatment of migraine attacks.Cephalalgia1985;5(suppl 3):554–5.
3.
KrauseKHBleicherMA.Dihydroergotamine nasal spray in the treatment of migraine attacks.Cephalalgia1985;5(suppl 3):138–9.
4.
PaviaTEsperancaPMarcelinoLAssisG.A double blind trial with dihydroergotamine spray in migraine crisis.Cephalalgia1985;5(suppl 3):140–1.
5.
RohrJDufrenseJJ.Dihydroergotamine nasal spray for the treatment of migraine attacks: a comparative double-blind crossover study with placebo.Cephalalgia1985;5(suppl 3):142–3.
6.
EkbomK.A questionnaire in the diagnosis of chronic headache.Sandorama1979;1:28–34.
